Skip to Content

Kazia Therapeutics Ltd NVGNF

Rating as of

Morningstar’s Analysis

Valuation
Currency in USD
Is it the right time to buy or sell?
Find out with Morningstar Premium
Is it the right time to buy or sell?
Find out with Morningstar Premium

1-Star Price

PREMIUM

5-Star Price

PREMIUM

Economic Moat

PREMIUM

About Quantitative Ratings

Morningstar Quantitative ratings for equities (denoted on this page by) are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies withratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating. Click here for more on how to use these ratings.

Company Profile

Business Description

Kazia Therapeutics Ltd is an oncology-focused biotechnology company, developing innovative anti-cancer drugs. The group is developing GDC-0084, a potential treatment for glioblastoma; Cantrixil, being developed for the treatment of ovarian cancer; and Others.

Contact
300 Barangaroo Avenue, Level 24
Sydney, NSW, 2000, Australia
T +61 294724101
Sector Healthcare
Industry Biotechnology
Most Recent Earnings Jun 30, 2008
Fiscal Year End Jun 30, 2021
Stock Type
Employees 5